Etsy (ETSY) came out with quarterly earnings of $0.25 per share, missing the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.41 per share a year ago.
Forge Global Holdings, Inc. (FRGE) Reports Q2 Loss, Tops Revenue Estimates — Negative
FRGE Zacks Investment Research — July 30, 2025Forge Global Holdings, Inc. (FRGE) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to a loss of $1.2 per share a year ago.
Hayward Holdings, Inc. (HAYW) Q2 Earnings and Revenues Beat Estimates — Positive
HAYW Zacks Investment Research — July 30, 2025Hayward Holdings, Inc. (HAYW) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.21 per share a year ago.
Vita Coco Company, Inc. (COCO) Q2 Earnings and Revenues Surpass Estimates — Positive
COCO Zacks Investment Research — July 30, 2025Vita Coco Company, Inc. (COCO) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.32 per share a year ago.
ProPetro Holding (PUMP) Reports Q2 Loss, Lags Revenue Estimates — Negative
PUMP Zacks Investment Research — July 30, 2025ProPetro Holding (PUMP) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to a loss of $0.03 per share a year ago.
Reynolds Consumer Products (REYN) Surpasses Q2 Earnings and Revenue Estimates — Positive
REYN Zacks Investment Research — July 30, 2025Reynolds Consumer Products (REYN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.46 per share a year ago.
Stepan Co. (SCL) Q2 Earnings and Revenues Lag Estimates — Negative
SCL Zacks Investment Research — July 30, 2025Stepan Co. (SCL) came out with quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.41 per share a year ago.
Stifel Financial (SF) Tops Q2 Earnings and Revenue Estimates — Positive
SF Zacks Investment Research — July 30, 2025Stifel Financial (SF) came out with quarterly earnings of $1.71 per share, beating the Zacks Consensus Estimate of $1.65 per share. This compares to earnings of $1.6 per share a year ago.
Idex (IEX) Q2 Earnings and Revenues Beat Estimates — Positive
IEX Zacks Investment Research — July 30, 2025Idex (IEX) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.06 per share a year ago.
Tradeweb Markets (TW) Beats Q2 Earnings and Revenue Estimates — Positive
TW Zacks Investment Research — July 30, 2025Tradeweb Markets (TW) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.7 per share a year ago.
SunCoke Energy (SXC) Lags Q2 Earnings Estimates — Negative
SXC Zacks Investment Research — July 30, 2025SunCoke Energy (SXC) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.25 per share a year ago.
Bloomberg reports that there is a threat that another Ford family member will run the company when Bill Ford, the current executive chair, steps down.
Last month, recent Wall Street AI darling Palantir announced a new partnership with Teletracking to use its AI suite in conjunction with the latter's platform to optimize healthcare operations and organizational decision-making capabilities.
Amazon.com (NASDAQ:AMZN) is scheduled to report its earnings on Thursday, July 31, 2025. For event-driven traders, understanding historical patterns around these announcements can provide a strategic edge.
CVS Health (NYSE:CVS) is scheduled to announce its earnings on Thursday, July 31, 2025. For event-driven traders, analyzing the stock's historical behavior around earnings releases can provide valuable context.
SALT LAKE CITY , July 30, 2025 /PRNewswire/ -- FatPipe, Inc. (NASDAQ: FATN) ("FatPipe" or the "Company"), a pioneer in enterprise-class, application-aware, secure software-defined wide area network ("SD-WAN") solutions that provide the highest levels of reliability, security, and optimization for Wide Area Networks (WANs), today announced its first quarter fiscal year 2026 results for the period ended June 30, 2025. Q1 Highlights Successfully completed initial public offering on the Nasdaq Capital Market Total product revenue grew 16.2% compared to the first quarter of fiscal 2025.
BDC Investors: Prepare For An Imminent Market Rotation — Negative
ARCC BIZD BXSL Seeking Alpha — July 30, 2025Despite my long-term bullish stance on BDCs, I believe the sector is primed for a correction and may deliver subpar total returns ahead. In fact, I would suggest total return focused investors rotating out of the BDC space to avoid a 1-3 year period of underperformance. Since my strategy is focused on high durable cash flows and long-term NAV stability, I remain invested in BDCs (although, with a prudent strategy).
Amentum is very well-positioned to benefit from the new EU defense deal, given its established presence in the EU already. Any future contracts will be with pre-vetted partners. The company's diverse offerings in military tech, logistics, and AI-enabled solutions make it a critical partner for expanding U.S. and EU defense initiatives. Despite recent contract wins and a strong backlog, Amentum's stock remains undervalued compared to peers, offering significant upside potential.
The REESE'S and OREO® Brands Announce Iconic Collaboration, Finally Giving Fans What They Have Been Asking For — Neutral
HSY MDLZ PRNewsWire — July 30, 2025Introducing the REESE'S OREO® Cup and OREO® REESE'S Cookie – a two-way collaboration between America's #1 Candy and #1 Cookie. HERSHEY, Pa.
Illumina enhances flagship assay to accelerate access to comprehensive tumor profiling — Neutral
ILMN PRNewsWire — July 30, 2025Illumina TruSight™ Oncology 500 v2 research assay is now available with built-in HRD biomarker detection, faster turnaround time, and lower tissue sample input Illumina's growing research and clinical oncology portfolio broadens access to critical biomarker testing SAN DIEGO , July 30, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive genomic profiling (CGP) is a critical tool to accelerate access to precision medicine by providing a molecular tumor profile to labs advancing research in therapy selection and clinical trial …